Key clinical point: Tumor testing for triage of HGSOC patient to confirmatory genetic testing may be cost-effective.
Major finding: Tumor testing yields an incremental cost-effectiveness ratio (ICER) of $127,000 per year of life gained.
Study details: A cost-efficacy analysis.
Disclosures: Dr. Kwon has received research funding from AstraZeneca.
Kwon J et al. SGO 2019: Abstract 5.